Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129362 · ClinicalTrials.gov registry record
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
A clinical trial, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- 1,195
- Enrollment target
NCT01129362 is a clinical trial that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 1,195 participants.
The verdict
NCT01129362 has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- 1,195 participants
- Enrollment target
Study Summary
The purpose of this cohort study is to determine vaccine-specific rates of pertussis disease during the period of the study, among Wisconsin residents younger than 60 months of age (the Surveillance Population), and to descriptively compare the proportion of such persons vaccinated with Pentacel® vaccine who acquire pertussis disease to the proportion of such persons vaccinated with any other Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) vaccine who acquire pertussis disease. Primary Objective: To determine the rates and relative risk of pertussis disease among Surveillance Population members who have received Pentacel vaccine or another pertussis vaccine.
Interventions
- BIOLOGICAL Pentacel® (DTaP-IPV/Hib)
- BIOLOGICAL Other Pertussis Vaccines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,195 participants |
| Start Date | 2010-02-08 |
| Est. Completion | 2014-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01129362
The ClinicalTrials.gov registry entry for NCT01129362 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pentacel® (DTaP-IPV/Hib) is the first listed.
NCT01129362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01129362 about?
NCT01129362 is a clinical study titled "Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines". The purpose of this cohort study is to determine vaccine-specific rates of pertussis disease during the period of the study, among Wisconsin residents younger than 60 months of age (the Surveillance Population), and to descriptively compare the proportion of such persons vaccinated with Pentacel® va...
What is the current status of trial NCT01129362?
This trial is currently completed. The enrollment target is 1,195 participants. The study started on 2010-02-08. Estimated completion is 2014-12-30.
What interventions are being tested in trial NCT01129362?
The interventions under investigation include: Pentacel® (DTaP-IPV/Hib) (BIOLOGICAL), Other Pertussis Vaccines (BIOLOGICAL).
Who is sponsoring clinical trial NCT01129362?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.